Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
Talphera will release its third quarter 2024 financial results on November 13, 2024 after market close.
Rhea-AI Summary
Talphera will release its third quarter 2024 financial results on November 13, 2024 after market close. The company will also host a live webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a business update. The webcast can be accessed through the Investors section of Talphera's website and will include a slide presentation. A replay will be available for 90 days post-event. Investors can join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using the conference ID 89949.
Positive
- None.
Negative
- None.
News Market Reaction – TLPH
In the trading session that priced this news, TLPH declined 1.22%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast Information
The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
Conference Call Information
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-third-quarter-2024-financial-results-and-corporate-update-call-and-webcast-on-wednesday-november-13-2024-302297952.html
SOURCE Talphera, Inc.